Contagion Editorial Team

A small subset of people living with HIV (PLWH) can naturally suppress the virus without medication.

The antibody profile in the blood of patients who have had the virus is extremely variable and this may modify the response to the treatment.

The shot will be its NanoFlu/NVX-CoV2373 vaccine using the company’s Matrix-M adjuvant platform.

FluGen announced its vaccine candidate, Bris2007 M2SR, induced neutralizing antibodies against infection and illness following a challenge with an antigenically distinct virus.

This therapy becomes the first single-dose infusion to treat acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.

In the second installment of an interview, members of the FlowMetric Life Sciences' leadership discuss how their technology might aid possible COVID-19 vaccine booster shots, how immunocompromised patients respond to vaccines, and other vaccines where their platform may be used.

FlowMetric, Inc., discusses its VaxEffect, an immune monitoring platform and how it can be used to measure COVID-19 vaccine responses.

The company’s mRNA-1010 is a seasonal influenza vaccine candidate that is targeting A H1N1, H3N2, influenza B Yamagata, and Victoria lineages.

The therapy, developed by Lupin Pharmaceuticals, now includes the treatment of trichomoniasis in adults patients and their partners.

This event will be a free, virtual event in July with expert speakers and survivors.

The organizations set out 3 recommendations for initial and recurrent C diff treatment.

Investigators looked at data from 3 analyses showed a reduction in mortality was observed across a spectrum of baseline oxygen requirements, at different timeframes, over the course of the pandemic, and in various geographies.

Paratek’s omadacycline (Nuzyra) is granted approval for an oral-only dosing regimen in adults.

The European Union (EU) agrees to look at easing restrictions for travelers from outside the continent, depending on vaccine or country status.

The Biden Administration plans to donate the AstraZeneca vaccines globally upon clearance of safety reviews.

The Centers for Disease Control and Prevention (CDC) announced that doing so offers very little in terms of protecting against transmission of the airborne virus.

The federal agency said people who are fully vaccinated “are less likely to get and spread COVID-19,” and can travel safely in the United States.

This partnership of recognized experts provided feedback about a variety of topics related to the virus.

The international organization offers guidance on various groups and if they should be consider getting the vaccine.

The Aptima HIV-1 Quant Dx assay is the first in the US to be able to make such a claim.

This guidance comes less than 24 hours after FDA grants an EUA for its use combined with baricitinib.

Bamlanivimab should be administered as soon as possible after a positive test, and within 10 days of developing symptoms, Eli Lilly said.

In a survey, a panel of experts sees the American response as problematic and weighs in on universal masking.

This action comes less than 24 hours after the J&J vaccine was paused.

As concerns are raised about prospective vaccines and their safety and efficacy, infectious disease experts offer support and insights about the development process.

Shionogi announces approval of cefiderocol for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Join us tomorrow for an informative discussion on CDC guidance and insights from medical experts on navigating a way back to in-school learning.

A study suggests that both have similar cycle thresholds but the virus lays dormat in an overwhelming majority of asymptomatic patients.

MJH Life Sciences is presenting a webinar today on this important topic.

A discussion between providers on 3 studies related to the antiviral.